2-METHYL-QUINAZOLINES

The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufactur...

Full description

Saved in:
Bibliographic Details
Main Authors SCHRODER, Jens, WORTMANN, Lars, SAUTIER, Brice, BOHNKE, Niels, BADER, Benjamin, PETERSEN, Kirstin, MOOSMAYER, Dieter, WANG, Qiuwen, VON NUSSBAUM, Franz, WENGNER, Antje Margret, LIENAU, Philip, SCHICK, Hans, BRIEM, Hans, HILLIG, Roman, EIS, Knut
Format Patent
LanguageEnglish
Published 28.07.2022
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions.The 2-methyl substituted quinazoline compounds of general formula (I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.
Bibliography:Application Number: US201816496825